High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
Natasha Vinod, Duhyeong Hwang, Salma H. Azam, Amanda E.D. Van Swearingen, Elizabeth Wayne, Sloane Christian Fussell, Marina Sokolsky‐Papkov, Chad V. Pecot, Alexander V. Kabanov
Abstract
immune response. Our study demonstrates the promise of poly(2-oxazoline)-formulated Resiquimod for treating metastatic NSCLC.
Topics & Concepts
AdenocarcinomaLungCancer researchAgonistImmune systemMicelleLung cancerMedicineChemistryCancerInternal medicineImmunologyReceptorAqueous solutionPhysical chemistryCancer Immunotherapy and BiomarkersLung Cancer Research StudiesImmunotherapy and Immune Responses